ClinicalTrials.gg
Active, not recruitingNCT06902519Updated Sep 3, 2026

Study of GS-0151 in Participants With Rheumatoid Arthritis

A Phase 1 interventional study of GS-0151 and Placebo in Rheumatoid Arthritis, sponsored by Gilead Sciences. Active, not recruiting at 35 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Arthritis, Rheumatoid by Gilead Sciences — none open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Gilead Sciences.

Enrollment
5th of 12
65 · median 49
Started
2025
the only one that year
Phase 1
6 of 12
none open now
Registered
12th of 12
by date

Among the 12 studies in Arthritis, Rheumatoid by Gilead Sciences, this one is the 5th largest by enrollment, is the only one that started in 2025, is one of 6 in phase 1, and was the 12th registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 12 studies in Arthritis, Rheumatoid by Gilead Sciences is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Arthritis, Rheumatoid by Gilead Sciences as a file.
02

Study summary

The goal of this clinical study is to learn more about the study drug GS-0151. The study is done to find how safe, well-tolerated the drug is. This will also assess how the drug is absorbed, modified, distributed and cleared from the body (the pharmacokinetics (PK) of the drug), when given multiple times to participants with rheumatoid arthritis (RA).

The primary objectives of this study is to assess the safety and tolerability of multiple ascending doses of GS-0151 in participants with RA and to characterize the PK of GS-0151 following multiple doses of GS-0151 in participants with RA.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Medical History/Physical Characteristics; All Cohorts:

  • Individuals must not be on a biologic disease-modifying antirheumatic drug (b/tsDMARD) on Day 1 and must have discontinued all b/tsDMARDs (including biosimilars and generics) at least 4 weeks prior to Day 1 with the exception of B cell-depleting agents (eg, rituximab), which must be discontinued for at least 6 months prior to Day 1.
  • Ongoing treatment with at least 1 but no more than 2 protocol-permitted conventional synthetic disease-modifying antirheumatic drug (csDMARDs) for at least 12 weeks, at a stable dose for at least 6 weeks prior to Day 1 and remain stable throughout the treatment period:

    1. Use of oral, intramuscular (IM), or subcutaneous(ly) (SC) methotrexate 7.5 to 25 mg/week. Individuals on methotrexate must be receiving folic or folinic acid supplementation at a stable dose.
    2. Oral hydroxychloroquine ≤ 400 mg/day or chloroquine ≤ 250 mg/day.
    3. Oral sulfasalazine 1 to 3 g/day.
    4. Oral leflunomide 10 to 20 mg/day.
  • Use of oral of no more than 10 mg prednisone or equivalent per day is allowed if the dose is stable for at least 14 days prior to Day 1. Inhaled corticosteroids for stable medical conditions are allowed but must have been at a stable dose for at least

    1 week prior to the first dose of study drug. Occasional topical corticosteroids are permitted.

  • Where nonsteroidal anti-inflammatory drug (NSAIDs) or acetaminophen are used, the dose must be stable for at least 1 week prior to Day 1
  • Individuals must have discontinued all high-potency opiates at least 1 week prior to Day 1.

Cohort 3 Only:

  • Individuals must meet all of the following cohort-specific inclusion criteria, in addition to meeting the inclusion criteria for all individuals , to be eligible for participation in Part B:

Moderately to severely active RA defined by the following:

Screening and Day 1:

  1. 6 or more tender joints on the tender joint count based on 68 joints (TJC68), AND.
  2. 6 or more swollen joints on the swollen joint count based on 66 joints (SJC66). The distal interphalangeal joints should be evaluated but not included in the total count to determine eligibility.

    Screening Only

  3. Have a hsCRP ≥

    • Inadequate response or intolerance to at least 1 but no more than 3 b/tsDMARDs with no more than 2 mechanisms of action. A lack of response is defined as documented continued or recurrent disease activity after at least 12 weeks of treatment of RA. Intolerance is defined as any documented adverse effect associated with a b/tsDMARD used according to its respective label.

Laboratory Assessments:

Cohort 3 Only:

  • Anti-cyclic citrullinated peptide antibody (Anti-CCP) positive and/or rheumatoid factor (RF) positive

Key Exclusion Criteria:

Medical Conditions; All Cohorts:

  • Have a diagnosis of any generalized musculoskeletal disorder that would interfere with study procedures or assessments per the discretion of the investigator.
  • History of opportunistic infection or immunodeficiency syndrome that would put the individual at risk, as per investigator's judgment.
  • Active infection that is , per investigator's judgment, or any infection requiring hospitalization or treatment with intravenous anti-infectives within 60 days of screening; or any infection requiring oral anti-infective therapy within 30 days of screening.
  • History of or current moderate to severe congestive heart failure ( class III or IV), or within the last 6 months prior to screening.
  • History of lymphoproliferative disease or possible current lymphoproliferative disease.
  • History of organ or bone marrow transplant.
  • Have a history of major surgery (requiring regional block or general anesthesia) within the last 12 weeks prior to screening or planned major surgery during the study.
  • History of an infected joint prosthesis or other implanted device with the prosthesis or device still in situ.
  • Clinically significant abnormalities at screening, including electrocardiographic interval between the beginning of the Q wave and termination of the T wave, representing the time for both ventricular depolarization and repolarization to occur () interval corrected for heart rate using the Fridericia formula (QTcF) > 450 msec, or hypokalemia if recurrent or persistent \< 3.0 mmol/L, or family history of long QT syndrome

Prior/Concurrent Therapy or Clinical Study Experience:

  • Administration of a 4 weeks prior to Day 1 or planned throughout the study.
  • Participation in any drug/device clinical study within 4 weeks or 5 half-lives prior to screening, whichever is longer. Exposure to investigational biologics should be discussed with the sponsor.

Diagnostic Assessments; All Cohorts:

  • Any positive tuberculosis (TB) test using interferon-gamma release assay (IGRA) performed by central laboratory at screening. Tests with inconclusive results may be repeated one time. If an inconclusive test is repeated and is returned with inconclusive results a second time, the individual will be excluded from the study. Individuals with a history of latent or active TB who have been treated with a full course of treatment, as per local guidelines, are eligible without the need for an IGRA at screening. Appropriate documentation of prior treatment is required.
  • Evidence of active virus (HCV) infection. Individuals with positive HCV Ab at screening require reflex testing for HCV ribonucleic acid (RNA). Individuals with positive HCV Ab but negative HCV RNA viral load are eligible per investigator judgment and require HCV viral load monitoring on Day 85 and Day 169.
  • The results of the following laboratory tests performed at the central laboratory at screening meet any of the criteria below (out-of-range laboratory values may be rechecked 1 time, per investigator's judgment, before individual is considered a screen failure):

    1. \< 10.0 g/dL (SI: \< 100 g/L)
    2. White blood cells \< 3.0 x 10\^3 cells/mm\^3 (SI: \< 3.0 x 10\^9 cells/L)
    3. Neutrophils \< 1.5 x 10\^3 cells/mm\^3 (SI: \< 1.5 x 10\^9 cells/L)
    4. Lymphocytes \< 1.0 x 10\^3 cells/mm\^3 (SI: \< 1.0 x 10\^9 cells/L)
    5. \< 100 x 10\^3 cells/mm\^3 (SI: \< 100 x 10\^9 cells/L)
    6. (ALT) or aspartate aminotransferase (AST) ≥ 1.5 x upper limit of normal (ULN)
    7. Total level ≥ 2 x ULN unless the individual has been diagnosed with Gilbert's disease and this is clearly documented
    8. \< 50 mL/min (SI: \< 0.83 mL/s) based on the Cockcroft-Gault formula

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Part A: Cohort 1 (GS-0151 Dose A)

    Participants with RA will be randomized to receive Dose A of GS-0151 up to 12 weeks.

    Drug: GS-0151

  • Placebo comparator
    Part A: Cohort 1 (Placebo)

    Participants with RA will be randomized to receive placebo up to 12 weeks.

    Drug: Placebo

  • Experimental
    Part A: Cohort 2 (GS-0151 Dose B)

    Participants with RA will be randomized to receive Dose B of GS-0151 up to 12 weeks.

    Drug: GS-0151

  • Placebo comparator
    Part A: Cohort 2 (Placebo)

    Participants with RA will be randomized to receive placebo up to 12 weeks.

    Drug: Placebo

  • Experimental
    Part B: Cohort 3 (GS-0151 Dose C)

    Participants with moderately to severely active RA will be randomized to receive Dose C of GS-0151.

    Drug: GS-0151

  • Placebo comparator
    Part B: Cohort 3 (Placebo)

    Participants with moderately to severely active RA will be randomized to receive placebo.

    Drug: Placebo

Interventions

  • DrugGS-0151

    Administered for 12 weeks

  • DrugPlacebo

    Administered for 12 weeks

06

What researchers measure

Primary outcomes

  1. Cohort 1, 2 and 3: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

    Time frame: First dose up to 19 Weeks post end of treatment at Week 12

  2. Cohort 1, 2 and 3: Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities

    Time frame: First dose up to 19 Weeks post end of treatment at Week 12

  3. Cohorts 1, 2 and 3: Percentage of Participants Experiencing Serous Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Discontinuation

    Time frame: First dose up to 19 Weeks post end of treatment at Week 12

  4. Cohort 1, 2 and 3: Serum AUCtau Following the Last Dose of GS-0151

    AUCtau is defined as the area under the serum concentration versus time curve over the dosing interval.

    Time frame: Up to Week 12

  5. Cohorts 1, 2 and 3: Serum Cmax, Following the Last Dose of GS-0151

    Cmax is defined as the maximum observed plasma drug concentration.

    Time frame: Up to Week 12

  6. Cohorts 1, 2 and 3: Serum Tmax Following the Last Dose of GS-0151

    Tmax is defined as the time (observed time point) of Cmax.

    Time frame: Up to Week 12

Secondary outcomes

  1. Cohorts 1, 2, and 3: Percentage of Participants with Antidrug Antibodies (ADAs) During the Study

    Time frame: Up to Week 12

  2. Cohort 3: Change From Baseline in Disease Activity Score for 28 Joint Count Using C-Reactive Protein (DAS28-CRP) at Week 12 in Participants With Moderately to Severely Active RA

    The DAS28-CRP Score comprises tender joint count and swollen joint count based on a 28 joint assessment; patient's global assessment of disease activity and CRP. The DAS28-CRP Score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and hsCRP (CRP=hsCRP) for a total possible score of 1 to 9.4. Higher values indicate higher disease activity.

    Time frame: Baseline, Week 12

07

Study locations

35 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Mar 2027, 22 months after the start.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 22 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Mar 30, 2025
StartActual
May 14, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06902519
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 30, 2025
Start date
May 14, 2025
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 3, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion